N1,N2-Bis[[4-(2-pyridinyl)phenyl]methyl]- 1,2-ethanediamine manufacturers
- BC-1215
-
- $47.00
-
2026-07-14
- CAS:1507370-20-8
- Purity: 99.97%
- Supply Ability: 10g
|
| | N1,N2-Bis[[4-(2-pyridinyl)phenyl]methyl]- 1,2-ethanediamine Basic information |
| Product Name: | N1,N2-Bis[[4-(2-pyridinyl)phenyl]methyl]- 1,2-ethanediamine | | Synonyms: | BC-1215;N1,N2-Bis[[4-(2-pyridinyl)phenyl]methyl]- 1,2-ethanediamine;BC-1215
(BC 1215;1,2-Ethanediamine, N1,N2-bis[[4-(2-pyridinyl)phenyl]methyl]-;BC-1215 >=98% (HPLC);{[4-(pyridin-2-yl)phenyl]methyl}[2-({[4-(pyridin-2-yl)phenyl]methyl}amino)ethyl]amine;N1,N2-bis(4-(pyridin-2-yl)benzyl)ethane-1,2-diamine;Ligands for E3 Ligase,E3 ligase-recruiting Moiety,F-box protein 3 (Fbxo3),Inhibitor,inhibit,inflammation,MLE cells,BC 1215,PBMC cells,BC-1215,BC1215,U937 cells,TRAF | | CAS: | 1507370-20-8 | | MF: | C26H26N4 | | MW: | 394.51 | | EINECS: | | | Product Categories: | | | Mol File: | 1507370-20-8.mol | ![N1,N2-Bis[[4-(2-pyridinyl)phenyl]methyl]- 1,2-ethanediamine Structure](CAS/20180713/GIF/1507370-20-8.gif) |
| | N1,N2-Bis[[4-(2-pyridinyl)phenyl]methyl]- 1,2-ethanediamine Chemical Properties |
| Boiling point | 589.9±50.0 °C(Predicted) | | density | 1.125±0.06 g/cm3(Predicted) | | storage temp. | Keep in dark place,Sealed in dry,2-8°C | | solubility | DMSO: soluble2mg/mL, clear (warmed) | | pka | 9.05±0.20(Predicted) | | form | A crystalline solid | | color | white to beige | | InChI | InChI=1S/C26H26N4/c1-3-15-29-25(5-1)23-11-7-21(8-12-23)19-27-17-18-28-20-22-9-13-24(14-10-22)26-6-2-4-16-30-26/h1-16,27-28H,17-20H2 | | InChIKey | IXEPQJQQSLMESJ-UHFFFAOYSA-N | | SMILES | C(NCC1=CC=C(C2=NC=CC=C2)C=C1)CNCC1=CC=C(C2=NC=CC=C2)C=C1 |
| Hazard Codes | Xn | | Risk Statements | 22 | | WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | N1,N2-Bis[[4-(2-pyridinyl)phenyl]methyl]- 1,2-ethanediamine Usage And Synthesis |
| Description | BC-1215 (N1,N2-Bis[[4-(2-pyridinyl)phenyl]methyl]- 1,2-ethanediamine) is an inhibitor of F-box protein 3 (FBXO3; IC50 = 0.9 μg/mL for Il-1β release). It decreases FBXO3 interaction with F-box/LRR-repeat protein 2 (FBXL2) in a dose-dependent manner and prevents FBXO3-dependent ubiquitination of FBXL2. It also lowers expression of Tnf receptor-associated factors (TRAFs) 1-6 without affecting TRAF1-6 mRNA levels in resting and LPS-stimulated peripheral blood mononuclear cells (PBMCs). BC-1215 (100 μg, i.p., per animal) reduces plasma levels of the inflammatory cytokines Il-6, Tnf, and Il-1β and decreases peritoneal bacteria counts in a mouse model of cecal ligation and puncture-induced sepsis. It also reduces inflammation in mouse models of DSS-induced colitis, paw edema, and ear edema. | | Uses | BC-1215 is a F-box protein 3 (Fbxo3) inhibitor. BC-1215 works by antagonizing of Fbxo3 on TRAF cytokine signaling and exhibits a low IC50 in vitro. BC-1215 can be used for the research of inflammation[1]. | | in vivo | BC-1215 (i.p.; 100 μg) reduces bacterial-induced inflammationa[1]. | Animal Model: | Cecal ligation and puncture (CLP)-induced sepsis model[1] | | Dosage: | 100 μg | | Administration: | i.p. | | Result: | Significantly attenuated CLP-induced secretion of all three circulating pro-inflammatory cytokines and decreased bacterial counts in the CLP model. |
| | IC 50 | Fbxo3 | | References | [1] Chen BB, et al. A combinatorial F box protein directed pathway controls TRAF adaptor stability to regulateinflammation. Nat Immunol. 2013 May;14(5):470-9. DOI:10.1038/ni.2565 |
| | N1,N2-Bis[[4-(2-pyridinyl)phenyl]methyl]- 1,2-ethanediamine Preparation Products And Raw materials |
|